Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia

Infection Control and Hospital Epidemiology

Volumn 33, Issue 2, 2012, Pages 160-166

  Mascitti, Kara B ^a   Edelstein, Paul H ^b   Fishman, Neil O ^b   Morales, Knashawn H ^b   Baltus, Andrew J ^b   Lautenbach, Ebbing ^b  

^a ST LUKE S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RISK FACTOR; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE; YOUNG ADULT;

EID: 84855525548     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/663708     Document Type: Article

References (41)

1. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26(2): 166-174.
2. McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006;42(suppl 2):S65-S71.
3. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45(suppl 3):S191-S195.
4. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60(4):788-794.
5. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased van-comycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44(11):3883-3886.
6. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staph-ylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166(19):2138-2144.
7. Lodise TP, Graves J, Evans A, et al. Relationship between van-comycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vanco-mycin. Antimicrob Agents Chemother 2008;52(9):3315-3320.
8. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38(12):1700-1705.
9. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42(6):2398-2402.
10. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of meth-icillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46(2):193-200.
11. Wang J-L, Wang J-T, Sheng W-H, Chen Y-C, Chang S-C. Nos-ocomial methicillin-resistant Staphylococcus aureus (MRSA) bac-teremia in Taiwan: mortality analyses and the impact of van-comycin, MIC p 2 mg/L, by the broth microdilution method. BMC Infect Dis 2010;10(1):159.
12. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51(7):2582-2586.
13. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphy-lococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9(10):617-624.
14. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42(11):1652-1653.
15. Lodise TP, Miller CD, Graves J, et al. Predictors of high van-comycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 62(5):1138-1141.
16. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2007; 61(1):85-90.
17. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing-Eighteenth Informational Supplement. Wayne, PA: CLSI; 2008. CLSI document M100-S18.
18. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard-Ninth Edition. Wayne, PA: CLSI; 2006. CLSI document M2-A9.
19. CLSI. Methods for Dilutional Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-Seventh Edition. Wayne, PA: CLSI; 2006. CLSI document M7-A7.
20. Bannerman TL, Peacock SJ. Staphylococcus, micrococcus, and other catalase-positive cocci. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology. Washington, DC: ASM; 2007:390-411.
21. Biodisk A. E-test Technical Manual. http://www.abbiodisk.com/bd-litt_etm.html. Accessed February 18, 2011.
22. Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011;49(1): 177-183.
23. Fitzgibbon MM, Rossney AS, O'Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogene-ously glycopeptide-intermediate S. aureus. J Clin Microbiol 2007; 45(10):3263-3269.
24. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylo-coccus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2006;45(2):329-332.
25. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-e55.
26. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aerugi-nosa: assessment of risk factors and clinical impact. Am J Med 2006;119(6):e519-e525.
27. Quain RD, Barton TD, Fishman NO, Weiner MG, Lautenbach E. Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Int J Antimicrob Agents 2005;26(4):327-330.
28. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43(11):1130-1139.
29. MacAdam H, Zaoutis TE, Gasink LB, Bilker WB, Lautenbach E. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int J Antimicrob Agents 2006;28(4):325-332.
30. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. New York: Van Nos-trand Reinhold; 1982.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22(4):719-748.
32. Hosmer DO, Lemeshow SL. Applied Logistic Regression. New York: Wiley; 1989.
33. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49(8):907-916.
34. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129(1): 125-137.
35. Ender M, McCallum N, Adhikari R, Berger-Bachi B. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother 2004;48(6):2295-2297.
36. Bloemendaal AL, Fluit AC, Jansen WT, et al. Colonization with multiple Staphylococcus aureus strains among patients in European intensive care units. Infect Control Hosp Epidemiol 2009; 30(9):918-920.
37. Mongkolrattanothai K, Gray BM, Mankin P, et al. Simultaneous carriage of multiple genotypes of Staphylococcus aureus in children. J Med Microbiol 2010;60(3):317-322.
38. Noto MJ, Fox PM, Archer GL. Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(4):1221-1229.
39. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staph-ylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9(11):1415-1422.
40. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Che-mother 2006;50(7):2330-2336.
41. Keel RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococ-cus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis 2010;68(3):326-329.